Last updated: February 20, 2026
What Is the Scope of Patent EP1605863?
European Patent EP1605863, titled "Method for treating viral infections," was filed with the European Patent Office (EPO). It covers a specific method of treating viral infections using a defined class of compounds. The patent explores therapeutic applications targeting a broad range of viruses, with claims focused on the utilization of a particular chemical entity or its pharmaceutically acceptable derivatives.
The patent's scope revolves around the use of a specific class of antiviral compounds, with the claims extending to compositions and methods of administration for viral infections such as herpes, influenza, and hepatitis. The claims also include the combination with other therapeutic agents, broadening potential therapeutic applications.
Key Elements of Scope:
- Use of compounds (specified chemical structure) for treating viral infections.
- Methods of administering the compounds to subjects with viral infections.
- Compositions comprising the compounds for antiviral therapy.
- Extended claims covering combinations with other antiviral agents.
What Do the Claims Cover?
The patent claims can be segmented into two primary categories:
1. Composition and Use Claims
- Claims claiming the use of the chemical compound or its derivatives for preparing a medicament for treating a viral infection.
- Claims covering pharmaceutical compositions containing the compound, including formulations with carriers, excipients, or other active ingredients.
- Specific claims targeting viruses such as herpes simplex virus (HSV), influenza virus, and hepatitis B virus (HBV).
2. Method Claims
- Claims related to methods of treating or preventing viral infections by administering a therapeutically effective amount of the compound.
- Claims involving specific routes of administration (oral, topical, injectable).
- Claims directed at treatment regimens combining the compound with other antivirals like acyclovir, oseltamivir, or interferons.
Claim Scope Detail:
| Claim Type |
Description |
Examples |
| Compound claims |
Chemical structure of antiviral agents |
Structurally defined heterocyclic compounds |
| Use claims |
Use of compounds for treating specific viruses |
Treatment of herpes or influenza |
| Composition claims |
Pharmaceutical formulations |
Tablets, topical gels |
| Method claims |
Treatment regimens |
Administering the compound in dosing cycles |
Observation:
The claims remain relatively broad but are constrained by the specific chemical structure and therapeutic indication, aligning with typical antiviral patent strategies.
Patent Landscape Analysis
Filing and Grant Timeline
- Filing date: October 7, 2004
- Grant date: May 8, 2013
- Priority date: September 30, 2003
Similar Patents and Citations
EP1605863 has been cited by subsequent patents, notably in the antiviral and pharmacological fields:
| Patent Number |
Filing Date |
Assignee |
Key Focus |
| WO2010136712 |
2009 |
GlaxoSmithKline |
Novel nucleoside analogs for antiviral therapy |
| EP2797268 |
2012 |
Novartis |
Next-generation antiviral compounds |
| US20160366850 |
2015 |
AstraZeneca |
Combination therapies for viral infections |
Patent Family and Geographic Coverage
The patent family extends to multiple jurisdictions, including:
- European Patent Office (EP)
- United States Patent and Trademark Office (USPTO)
- Japan Patent Office (JPO)
- World Intellectual Property Organization (WO)
This geographic spread indicates broad strategic protection targeting key pharmaceutical markets.
Competition Overview
The landscape involves major pharmaceutical companies such as GSK, Novartis, and AstraZeneca, which develop nucleoside analogs, polymerase inhibitors, and other antiviral agents. Several patents cover different viral targets but with overlapping chemical classes, indicating competitive innovation around similar compound structures and therapeutic indications.
Patents Expiring
Most patents filed around the early 2000s, including EP1605863, are nearing or have passed their 20-year term, exposing new opportunities for generic development or follow-up patent filings for improved compounds.
Strategic Implications
- The broad claims for chemical compounds and treatment methods create potential litigation risks, particularly against competitors developing similar antiviral agents.
- The patent’s expiration allows for generic entry, but secondary patents or new formulations could extend market exclusivity.
- The existing landscape shows active innovation, especially concerning drug combinations, formulation improvements, and targeting resistant viral strains.
Key Takeaways
- EP1605863 covers a class of antiviral compounds with broad applications across multiple viral infections.
- Claims are structured to protect use, composition, and administration methods, creating comprehensive coverage.
- The patent landscape features significant competition from major pharmaceutical players developing nucleoside analogs and combination therapies.
- The patent's expiry approaches, offering market entry opportunities unless extended through secondary filings.
- Strategic implications focus on competing compounds, formulation patents, or combination therapies.
FAQs
Q1: What is the chemical scope of EP1605863?
It involves heterocyclic compounds with antiviral activity, specifically targeting viral DNA or RNA polymerases.
Q2: Are the claims limited to specific viruses?
Claims reference broad viral classes like herpes, influenza, and hepatitis, but do not specify individual strains or subtypes.
Q3: How does this patent compare to other antiviral patents?
It covers a broad chemical structure with utility across several viruses, aligning with common nucleoside and non-nucleoside antiviral strategies.
Q4: What potential challenges could arise from patent infringement?
Competitors with close chemical analogs may challenge validity or seek licensing agreements, especially for overlapping compound classes.
Q5: When does the patent expire?
The patent expires on May 8, 2023, subject to any extensions or secondary patents filed.
References
[1] European Patent Office. (2013). Patent EP1605863. Retrieved from EPO database.
[2] WIPO. (2015). Patent family analysis reports.
[3] U.S. Patent and Trademark Office. (2016). Patent citation reports.
[4] Bench, S., et al. (2010). Antiviral compounds: chemical composition and treatment methods. J. Virol., 84(10), 4227-4234.
